# Cannabis for MS Bladder Symptoms: What an Umbrella Review and Two Randomized Trials Show > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-ms-bladder-symptoms-evidence/ > **Published:** 2026-10-22T13:33:41-04:00 | **Last Modified / Clinically Audited:** 2026-10-22T13:38:18-04:00 > **Clinical Summary:** Does cannabis help MS bladder symptoms? A physician reviews a 34-review umbrella analysis and two randomized trials on incontinence and nocturia. --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella Review.. Clinical Insight | CED Clinic Lower urinary tract dysfunction is among the most common problems in multiple sclerosis, presenting as urgency, frequency, incontinence, or incomplete emptying. While standard anticholinergics and intradetrusor botulinum toxin injections offer documented efficacy, systemic adverse effects, urinary tract infections, and retention frequently disrupt compliance. In randomized trials, cannabinoids have reduced some bladder symptoms, most consistently nocturia and urinary frequency, although a nabiximols trial missed its primary incontinence endpoint. Clinicians must weigh symptom reduction against treatment tolerability, recognizing that current published literature demands more rigorous, randomized trials to establish clear hierarchical algorithms for complex neurogenic bladder presentations. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Managing Urinary Symptoms in Multiple Sclerosis: E. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42885333/) Cannabis for MS Bladder Symptoms: What an Umbrella Review and Two Randomized Trials Show Evidence cited: umbrella review of 34 systematic reviews and two randomized controlled trials (Oxford CEBM levels 1a to 1b; underlying evidence rated poor by the review authors)Direct Clinical Answer Cannabinoids have modest randomized-trial support for multiple sclerosis bladder symptoms: oral cannabis extract and THC reduced urge incontinence, and nabiximols improved nocturia and voiding frequency without significantly reducing incontinence. Animal studies suggest bladder CB1 receptors dampen overactive signaling. A urological evaluation should come first, and cannabinoids belong alongside standard care. **Umbrella review:** 34 systematic reviews; evidence rated poor**Key cannabinoid RCTs:** CAMS-LUTS (2006) and nabiximols (2010)**Most consistent benefit:** Nocturia and voiding frequency**Clinical perspective:** Benjamin Caplan, MD, board-certified family physician (ABFM) An umbrella review of thirty-four systematic reviews evaluates therapies for lower urinary tract dysfunction in multiple sclerosis. Cannabinoids show therapeutic potential alongside neuromodulation, while conventional medications present significant burdens of adverse side effects. What This Study Teaches Us This umbrella review screened 342 records and included 34 systematic reviews of treatments for MS-related lower urinary tract dysfunction. Pelvic floor muscle training and tibial nerve stimulation showed preliminary efficacy and safety, cannabinoids were among several options with suggested potential, and anticholinergics, botulinum toxin injections, and catheterization worked but carried considerable side effects. Why This Matters Bladder symptoms drive infections, poor sleep, and social withdrawal in MS, and many standard drugs are poorly tolerated, so knowing where cannabinoids fit, and how thin the evidence still is, helps patients and clinicians set realistic expectations. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceNeurourology and urodynamicsPublication Date2026Oct16Evidence LevelJournal Article, ReviewFocus AreaManaging Urinary Symptoms in Multiple Sclerosis: Evidence anLead AuthorsSina Hamzehzadeh, Donyasadat Hashemian, Saman Baharomid, Fateme Tahmasebi et al.DOI10.1002/nau.70492PMIDPMID: 42885333 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Mainstream headlines often claim natural therapies such as cannabis can replace standard bladder medications for multiple sclerosis patients. **Primary Journal Data:** The umbrella review of 34 systematic reviews found preliminary efficacy for cannabinoids, but noted the broader clinical trial evidence base across all modalities remains weak and inconclusive. **Dr. Caplan’s Clinical Verdict:** Cannabinoids offer meaningful symptom modulation for spastic bladder symptoms, yet they serve as adjuncts rather than outright replacements for individualized urological care. Primary Analysis | Management of Urinary Symptoms in Multip **Study Overview:** The authors followed PRISMA and Joanna Briggs Institute methods, searched PubMed, Scopus, Embase, and Web of Science, and appraised each included review for risk of bias. Of 342 screened records, 34 systematic reviews met inclusion criteria. Pelvic floor muscle training and tibial nerve stimulation had the clearest preliminary support, while alpha-blockers, cannabinoids, mirabegron, several neuromodulation approaches, and other therapies were described as having potential. Anticholinergics, desmopressin, intradetrusor botulinum toxin A, vanilloids, and catheterization were effective but caused considerable side effects. The authors concluded that the overall evidence base is poor, that well-designed randomized trials are lacking, and that treatment algorithms still need refinement. **Primary Source & Scope:** Published in *Neurourology and urodynamics* (2026Oct16) conducted by Sina Hamzehzadeh, Donyasadat Hashemian, Saman Baharomid, Fateme Tahmasebi et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42885333/) | **Primary Record:** DOI: 10.1002/nau.70492 | PMID: 42885333 How Strong Is This Evidence? An umbrella review sits high in the evidence hierarchy, but it can only be as strong as the reviews and trials beneath it, and these authors judged that base to be poor. For cannabinoids specifically, the two key randomized trials point in somewhat different directions. In the CAMS-LUTS substudy, oral cannabis extract and THC reduced urge incontinence episodes by 38% and 33%, compared with 18% on placebo ([Freeman et al., International Urogynecology Journal, 2006](https://doi.org/10.1007/s00192-006-0086-x)). In a 135-patient trial, nabiximols oromucosal spray did not significantly reduce incontinence episodes, its primary endpoint, but did improve nocturia, daily voids, and patient-rated bladder condition ([Kavia et al., Multiple Sclerosis, 2010](https://doi.org/10.1177/1352458510378020)).Freeman et al., International Urogynecology Journal, 2006. Where This Paper Deserves Skepticism Umbrella reviews inherit the weaknesses of the reviews they summarize, including small trials, short follow-up, and inconsistent outcome measures. The CAMS-LUTS analysis was a substudy of a larger spasticity trial, and neither cannabinoid trial tested the kinds of products sold in dispensaries today. What This Paper Does Not Show This publication does not establish universal treatment efficacy or substitute for personalized physician consultation. How This Fits With the Broader Clinical Conversation Bladder care in MS is moving toward stepped, individualized plans that begin with pelvic floor training and behavioral measures and add medication, neuromodulation, or botulinum toxin as needed. Cannabinoids may fit as an adjunct for patients who also have spasticity, pain, or poor sleep, but they do not replace a urological evaluation. Editorial framework informed by Hamzehzadeh et al., Neurourology and Urodynamics, 2026. Not a clinical guideline. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, this umbrella review is a useful reminder that a long list of treatment options is not the same as strong evidence for any one of them.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Cannabinoids have modest randomized-trial support for some MS bladder symptoms, especially nocturia and frequency, but the overall evidence base is weak, and new bladder symptoms deserve a urological evaluation first. [https://cedclinic.com/ask/](https://cedclinic.com/ask/)Ask about this study:[🦾MS and Spasticity](https://cedclinic.com/ask/)[🛡️Safety](https://cedclinic.com/ask/)[⚖️Dosing](https://cedclinic.com/ask/)[🔎This study's limits](https://cedclinic.com/ask/) Evidence Interpretation Guide Table of Contents - [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Cite This Article (AMA Style)](#Cite_This_Article_AMA_Style) - [Related](#Related) ## How to Interpret This Clinical Study Reading MS bladder research well means separating the umbrella review conclusions from the individual trials beneath them. ### Three Rules for Critical Reading **1. Check Study Design**Determine whether a cannabinoid finding comes from a [randomized trial](https://cedclinic.com/cannabidiol-effects-on-appetite/), an observational study, or an animal model. **2. Note Sample Size & Boundaries**Evaluate participant numbers, dosing regimens, and follow-up duration before generalizing conclusions. **3. Consult Qualified Physicians**Personalized treatment strategies should be established under professional medical supervision. Key Evaluation Question Does the evidence show fewer leaks, fewer nighttime trips, and better [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/), or only changes in bladder measurements? The Patient Question How can the specific findings from this study inform my current treatment and symptom goals? The Bottom Line Cannabinoids are a reasonable adjunct to discuss for MS bladder symptoms, not a first-line replacement for standard urological care. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for [patient care](https://cedclinic.com/france-cannabis-prohibition-impact/). #### Clinical Evidence Synthesis The umbrella review synthesized data from thirty-four systematic reviews addressing lower urinary tract dysfunction in multiple sclerosis. Evaluated interventions spanned non-pharmacological methods like pelvic floor muscle training, diverse neuromodulation strategies, and pharmacological agents including cannabinoids, anticholinergics, and botulinum toxin A. The analysis uncovered a consistent gap in primary study design. Although several therapies demonstrated clear capacity to suppress detrusor contractions or lower episode frequency, the high risk of bias across underlying trials limits definitive practice recommendations. Lens takeawaySystematic synthesis reveals promising preliminary signals across non-invasive therapies, yet high-quality randomized evidence remains sparse throughout current neurological literature. #### Patient Communication Urinary incontinence and sudden urgency create severe social distress, sleep disruption, and functional decline for individuals with multiple sclerosis. Patients frequently hide symptoms from care teams until accidents occur or chronic infections take hold. Clinicians should proactively initiate bladder health discussions at routine visits. Exploring adjunctive therapeutic options, including plant-based compounds or pelvic floor training, encourages open dialogue and restores patient agency in managing embarrassing symptoms. In everyday practice, evaluating patient considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Print one page per day and bring all three to your next appointment.Lens takeawayOpen clinical communication regarding neurogenic bladder dysfunction reduces emotional isolation and improves early engagement with supportive therapies. #### Dosing & Formulations Clinical protocols examining cannabinoids for neurogenic bladder dysfunction focus on balanced ratios of delta-9-tetrahydrocannabinol and cannabidiol. Randomized evidence is mixed: oral cannabis extract and THC reduced urge incontinence episodes in the CAMS-LUTS substudy, while a balanced THC and CBD oromucosal spray (nabiximols) improved nocturia and voiding frequency but not incontinence episodes. Nabiximols for MS bladder symptoms: what changedEndpointResult compared with placeboDaily urinary incontinence episodes (primary endpoint)No significant differenceNocturia episodesImproved (adjusted mean difference -0.28; p = 0.010)Overall bladder conditionImproved (-1.16; p = 0.001)Voids per dayImproved (-0.85; p = 0.001)Daytime voidsImproved (-0.57; p = 0.044)Patient Global Impression of ChangeImproved (p = 0.005)Incontinence quality of lifeFavored nabiximols; not statistically significant 135 randomized adults with MS and overactive bladder over 10 weeks. Source: Kavia RBC, et al. Multiple Sclerosis. 2010;16(11):1349-1359. [Titration must proceed slowly](/how-long-cannabis-takes-to-work-for-ms-spasticity/) to avoid exacerbating baseline neurological ataxia or fatigue. Initiating low evening doses allows patients to improve nocturnal bladder capacity while monitoring individual daytime sensitivity. In everyday practice, evaluating dosing considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayIncremental titration of balanced cannabinoid formulations minimizes sedation while optimizing daytime and nocturnal urinary bladder control. #### Safety & Side Effect Profile Established pharmacotherapies carry marked burdens. Anticholinergic drugs frequently produce severe dry mouth, constipation, and cognitive impairment, while intradetrusor botulinum toxin A carries a recognized risk of acute urinary retention and recurrent infections. Common cannabinoid side effects include dizziness, drowsiness, and dry mouth, and people with MS warrant extra attention to cognition, balance, and fall risk. Clinicians must still evaluate [drug-drug interactions](/cannabinoid-medication-interaction-checker/) involving hepatic cytochrome P450 enzymes when adding cannabinoids to complex neurological regimens. In everyday practice, evaluating safety considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayCannabinoids avoid urinary retention and anticholinergic burden but carry their own risks to cognition and balance, so the trade-off is individual. #### Regulatory & Policy Dynamics Regional discrepancies in cannabinoid scheduling significantly influence [patient access](https://cedclinic.com/virginia-cannabis-marketplace-timing/) to standardized pharmaceutical cannabis preparations. In jurisdictions where nabiximols is approved specifically for [multiple sclerosis spasticity](/cannabinoids-ms-spasticity-randomized-review/), off-label use for co-occurring bladder dysfunction sometimes follows. In regions lacking formal regulatory recognition, patients turn to local dispensary markets where product consistency, purity testing, and cannabinoid ratios vary widely. Establishing unified national standards ensures reliable access to medical-grade formulations. In everyday practice, evaluating regulatory considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayJurisdictional barriers continue to restrict patient access to standardized cannabinoid preparations, driving consumers toward inconsistent commercial retail products. #### Mechanisms & Physiology The [endocannabinoid system exerts direct control](/endocannabinoid-system-multiple-sclerosis-treatment-algorithm/) over micturition pathways. Cannabinoid CB1 receptors localize extensively within the human detrusor muscle, urothelium, and the spinal cord circuits governing autonomic bladder reflexes. In animal studies, activation of peripheral CB1 receptors reduces sensory afferent transmission from the bladder wall to the central nervous system. In principle, this peripheral effect could calm hyperactive detrusor contractions without completely blocking normal voluntary voiding reflexes. In everyday practice, evaluating mechanisms considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayAnimal studies suggest that bladder CB1 receptors dampen sensory signaling, a plausible but unproven explanation for symptom changes seen in human trials. #### Research Limitations Umbrella reviews inherently inherit the methodological flaws of the systematic reviews they assemble. Heterogeneous outcome measures across trials, varying from subjective symptom diaries to objective urodynamic testing, complicate direct cross-study comparisons. Many evaluated trials featured small sample sizes, short observation periods, and incomplete reporting on long-term safety. These structural limitations prevent investigators from establishing clear superiority among emerging interventions. In everyday practice, evaluating limits considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayVaried outcome measures and short follow-up periods within original clinical trials prevent researchers from establishing definitive treatment superiority rankings. #### Future Outlook Future urological management in multiple sclerosis lies in multi-modal protocols tailored to individual neurological phenotypes. Pairing pelvic neuromodulation with low-dose targeted pharmacotherapy or plant cannabinoids holds great clinical potential. Large-scale, blinded randomized trials using standardized urodynamic parameters are essential. Such investigations will clarify precise dosing thresholds and define which patient subgroups derive the greatest durable benefit. In everyday practice, evaluating outlook considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayCombining localized neuromodulation with targeted cannabinoid therapies offers a compelling roadmap for future rigorous clinical trials in neurogenic bladder care. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 400k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+for+MS+Bladder+Symptoms%3A+What+an+Umbrella+Review+and+Two+Randomized+Trials+Show&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-ms-bladder-symptoms-evidence%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-ms-bladder-symptoms-evidence%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+for+MS+Bladder+Symptoms%3A+What+an+Umbrella+Review+and+Two+Randomized+Trials+Show%20https%3A%2F%2Fcedclinic.com%2Fcannabis-ms-bladder-symptoms-evidence%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella Review.](https://pubmed.ncbi.nlm.nih.gov/42885333/) Related Reading at CED ClinicContinue exploring the evidence[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for chronic pain and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/)[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce [cannabis use](https://cedclinic.com/cannabis-use-patterns-young-adults-social-health/), clinical cessation discussions, and quitline uptake barriers. [More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) ## Frequently Asked Questions What is lower urinary tract dysfunction in multiple sclerosis? Lower urinary tract dysfunction in multiple sclerosis encompasses urgency, frequent daytime urination, nocturia, urinary retention, and involuntary leakage resulting from disrupted nerve communication between the brain, spinal cord, and bladder. What treatments did this umbrella review evaluate? The review examined thirty-four systematic reviews evaluating pelvic floor muscle training, tibial nerve stimulation, cannabinoids, anticholinergic medications, intradetrusor botulinum toxin A, alpha-blockers, and mirabegron. How effective are cannabinoids for MS-related bladder issues? In randomized trials, cannabinoids reduced nocturia and daily voiding frequency, and oral cannabis extract and THC reduced urge incontinence episodes in one large substudy, but a nabiximols trial did not significantly reduce incontinence episodes. The umbrella review rates the overall evidence base as poor. Why are traditional anticholinergic medications problematic for some MS patients? Anticholinergic drugs carry high rates of systemic side effects, including severe dry mouth, blurred vision, worsened constipation, and potential cognitive impairment, which can compound pre-existing neurological symptoms. How do cannabinoids act biologically on the bladder? Animal and tissue studies suggest that cannabinoids act on CB1 and CB2 receptors in the [bladder urothelium](/targeting-cannabinoid-receptors-in-bladder-sensory-pathways-may-alleviate-pain-of-cystitis/), detrusor smooth muscle, and spinal reflex loops, dampening hyperactive sensory afferents and easing uncoordinated bladder contractions. Which cannabinoid products have been studied for MS bladder symptoms? The two main randomized trials used different products: nabiximols, a roughly 1:1 THC and CBD oromucosal spray (Kavia et al., 2010), and oral cannabis extract or THC capsules in the CAMS-LUTS substudy (Freeman et al., 2006). No ratio has been established as best for bladder symptoms. Can non-pharmacological therapies help MS bladder symptoms? Yes, the review highlighted positive preliminary safety and efficacy for pelvic floor muscle training and tibial nerve stimulation as non-invasive, low-risk therapeutic options. Does this study recommend substituting standard MS medications with cannabis? No, the authors position cannabinoids as a promising option among diverse emerging therapies, noting that current research lacks conclusive head-to-head evidence to replace established primary care pathways. ### Cite This Article (AMA Style) Caplan B. Cannabis for MS Bladder Symptoms: What an Umbrella Review and Two Randomized Trials Show. *CED Clinic*. Accessed October 22, 2026. https://cedclinic.com/cannabis-ms-bladder-symptoms-evidence/ ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).